There've been several big pharmaceutical takeovers in recent months. But the latest $20-billion deal between Britain's GlaxoSmithKline and Switzerland's Novartis is no merger.
There have been several big pharmaceutical takeovers in recent months. But the latest $20-billion deal between Britain's GlaxoSmithKline and Switzerland's Novartis is no merger.
